Yeleswaram Krishnaswamy 4
4 · Rapport Therapeutics, Inc. · Filed Apr 14, 2026
Research Summary
AI-generated summary of this filing
Rapport Therapeutics (RAPP) CDO Y. Krishnaswamy Sells Shares
What Happened
Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics (RAPP), sold a total of 19,865 shares in three open-market transactions between April 10 and April 14, 2026, for aggregate proceeds of approximately $695,824. Transactions: 500 shares on 2026-04-10 at $34.98 ($17,490); 9,165 shares on 2026-04-13 at a weighted average $34.97 ($320,537); and 10,200 shares on 2026-04-14 at a weighted average $35.08 ($357,797). These were sales (code S) — dispositions of stock rather than purchases.
Key Details
- Dates & reported prices: 2026-04-10 (500 @ $34.98); 2026-04-13 (9,165 @ $34.97 weighted avg); 2026-04-14 (10,200 @ $35.08 weighted avg).
- Aggregate shares sold: 19,865; aggregate proceeds: ~$695,824.
- Shares owned after transaction: not specified in the filing.
- Footnotes: Sales were effected under a Rule 10b5-1 trading plan adopted Dec 10, 2025 (F1). The reported prices for 4/13 and 4/14 are weighted averages; transactions on those dates occurred across price ranges (4/13: $34.90–$35.15 per F2; 4/14: $34.90–$35.37 per F3). The reporting person will provide a per-price breakdown on request.
- Filing timing: Form 4 filed April 14, 2026 reporting transactions through April 10–14, 2026; the filing does not indicate a late-report flag.
Context
These sales were executed under a pre-established 10b5-1 plan, which schedules trades in advance and can be routine. Sales do not necessarily indicate a change in the insider's view of the company; purchases are generally considered more informative about bullish insider conviction.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-04-10$34.98/sh−500$17,490→ 286,016 total - Sale
Common Stock
[F1][F2]2026-04-13$34.97/sh−9,165$320,537→ 276,851 total - Sale
Common Stock
[F1][F3]2026-04-14$35.08/sh−10,200$357,797→ 266,651 total
Footnotes (3)
- [F1]These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.90 to $35.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.90 to $35.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.